Disclosed herein is a microparticle analyzing apparatus including a detecting portion configured to simultaneously detect a fluorescence generated from a microparticle in plural wavelength regions and a displaying portion configured to display thereon detection results in the plural wavelength regions in a form of a spectrum.

A spectroscopic imaging apparatus according to an embodiment of the present technology includes a spectroscopic section, an image sensor, and a control unit. The spectroscopic section disperses incident light for each wavelength. The image sensor is configured to be capable of setting an exposure time or a gain in a unit of a pixel, and detects light of each wavelength dispersed in the spectroscopic section. The control unit is configured to be capable of setting the exposure time or the gain of the image sensor in a unit of a predetermined pixel area.

Disclosed herein is a microparticle analyzing apparatus including a detecting portion configured to simultaneously detect a fluorescence generated from a microparticle in plural wavelength regions and a displaying portion configured to display thereon detection results in the plural wavelength regions in a form of a spectrum.

The invention provides novel non-invasive in vitro methods for assessing the metabolic condition of oocytes and/or embryos with fluorescence lifetime imaging microscope, that can be used, for example, in assessment of oocytes and embryos in assisted reproductive technologies.

The disclosure relates to a system for identifying medicines, comprising a first measurement device for identifying, from the top, at least one first medicine deposited in a compartment of a pill box and analysing at least one identifying characteristic of the first medicine; and a second measurement device for identifying, from the bottom, at least one second medicine deposited in the compartment of said pill box and analysing at least one identifying characteristic of the second medicine. The system comprises a device for comparing the characteristic of the first medicine and the characteristic of the second medicine, for determining at least one validated medicine and comparing the characteristic of the validated medicine with medicine signature characteristics. The system also comprises a validation device for obtaining an identified content for the compartment and comparing the identified content with a prescription. Methods for identifying and validating medicines are also disclosed.

A spectrally encoded fluorescence imaging system includes a multi-wavelength excitation light source emitting excitation light for illuminating a sample, optical components for introducing spectral encoding to focus different wavelengths of the excitation light at different positions in the sample to generate fluorescence at different, spatial positions, and band-shifting florescence imaging probes exhibiting excitation-dependent emission band, causing the fluorescence generated at different spatial positions to exhibit different band shifts, such that image information is encoded in the band-shifted fluorescence spectrums for parallel detection by a spectrometer or arrayed detectors operable to resolve different wavelengths.

A fluorescence observation apparatus according to an embodiment of the present technology includes a stage, an excitation section, and a spectroscopic imaging section. The stage is capable of supporting a fluorescently stained pathological specimen. The excitation section irradiates the pathological specimen on the stage with a plurality of line illuminations of different wavelengths, the plurality of line illuminations being a plurality of line illuminations situated on different axes and parallel to a certain-axis direction. The spectroscopic imaging section includes at least one imaging device capable of separately receiving pieces of fluorescence respectively excited with the plurality of line illuminations.

A microscopy method includes illuminating an object with illumination light, recording a first color image of the illuminated object by a color image sensor suitable for recording colors of a first gamut, producing a second color image of the object, the second color image including pixels that each have assigned a color from a second gamut, depicting the second color image by a display apparatus suitable for rendering colors of the second gamut, wherein the producing the second color image includes determining the colors at the pixels of the second color image by applying a color transfer function to the colors of the corresponding pixels of the first color image, the color transfer function mapping input colors onto output colors, and the color transfer function mapping those input colors that belong to the first gamut but not to the second gamut onto output colors that belong to the second gamut.

High-throughput hyperspectral imaging systems are provided. According to an aspect of the invention, a system includes an excitation light source; an objective that is configured to image excitation light onto the sample, such that the excitation light causes the sample to emit fluorescence light; a channel separator that is configured to separate the fluorescence light into a plurality of spatially dispersed spectral channels; and a sensor. The excitation light source includes a light source and a plurality of lenslet arrays. Each of the lenslet arrays is configured to receive light from the light source and to generate a pattern of light, and the patterns of light generated by the lenslet arrays are combined to form the excitation light. The objective is configured to simultaneously image each of the patterns of light to form a plurality of parallel lines or an array of circular spots at different depths of the sample.

Provided are a mobile phone-based biological testing method and apparatus. The method includes: selecting N kinds of quantum dots of specific wavelengths to label N to-be-tested biomarkers in a sample, where N is 1, 2 or 3; exciting to-be-tested biomarker-quantum dot compounds using excitation light; photographing the above excited compounds for multiple times, so as to obtain a first original image file in a RAW format with a 16-bit depth; photographing unlabeled quantum dots to obtain a second original image file in a RAW format with a 16-bit depth; calculating a matrix of transition coefficients of fluorescence intensities of the quantum dots received by channels in the second original image file; calculating a fluorescence intensity of each of the to-be-tested biomarker-quantum dot compounds in the first original image file; and obtaining a concentration of each of the to-be-tested biomarkers according to the fluorescence intensity, so as to complete biological testing.